Proteinchips - 500 Beiträge pro Seite

[coelacanth]

Ist hier jemand in Ciphergen investiert ?
Meiner bescheidenen Ansicht nach sind Proteinchips
die Nachfolger der DNA Chips und haben `ne große Zukunft.
Die Aufgabe ist herauszufinden, welche Proteine in den
Genen kodiert sind. Das ist `ne mühselige Aufgabe und
Arbeitsvereinfachung ist angesagt. Da helfen dann
Proteinchips so wie die DNA-Chips von Affymetrix dem
Genomprojekt sehr geholfen haben.

[ANBU]

Die Proteinchip-Forschung steht wirklich vor einem großen Wachstum. Das besagt auch eine neue Studie der DZ-Bank. Ciphergen Biosystems ist auf diesem Gebiet schon sehr weit und auch das letzte Quartalsergebnis lag weit über Plan. Demzufolge ist der Kurs in den letzten Wochen kräftig gestiegen. Für einen Einstieg ist es m. E. jedoch noch nicht zu spät, denn schließlich kommt der Kurs von 32 USD. Ich rechne für das erste Quartal mit Kursen von 10-12 Euro. Auf Jahressicht sollten Kurse von 20 Euro erreichbar sein. Ciphergen kooperiert u.a. mit der am Neuen Markt notierten Medigene AG.
Ciphergen Biosystems wird auch an deutschen Börsen unter der WKN 927168 allerdings mit geringen Umsätzen gehandelt.
Für mich ist Ciphergen eine der noch unentdeckten Biotechperlen und die Aktie für das Jahr 2002.

[panik]

Ciphergen Announces Expanded Use of its SELDI ProteinChip(R) Technology And Biomarker Discovery Center(R) Compound Profiling Services with Novartis
Tuesday November 5, 4:16 pm ET


FREMONT, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) today announced that Novartis has expanded its use of SELDI ProteinChip® technology and has entered into a master agreement to cover certain compound profiling projects with Ciphergen`s Biomarker Discovery Centers®.
ADVERTISEMENT


Novartis has now acquired multiple ProteinChip Systems, one of which is being used in its Oncology Business Unit. Ciphergen`s ProteinChip Systems are being used for a variety of purposes, most notably protein Expression Difference Mapping(TM) to discover biomarkers for drug discovery as well as for clinical and preclinical development purposes. Supported by Ciphergen`s field scientists, this decentralized use of the technology fits Ciphergen`s vision of putting a powerful protein analysis tool in the hands of biologists immersed in the biology of their disease or functional focus.

Under the master agreement, Ciphergen may conduct multiple outsourced projects from Novartis. In the first such project, Ciphergen`s Biomarker Discovery Center in Malvern, PA has launched a study with Novartis` Oncology Business Unit to profile protein expression effects of their compounds. This study will compare serum samples from patients who responded to treatment with a drug candidate to samples from patients who did not respond.

"We`re delighted that Novartis has become such a key account through its use of our ProteinChip Systems and Biomarker Discovery Center collaborative services," commented William E. Rich, President and CEO of Ciphergen.

"We are optimistic that through ProteinChip Array compound profiling we will develop key insights into the optimal applications of our drugs to benefit patients," stated David Parkinson, M.D., Vice President and Global Head, Novartis Oncology Translational Therapeutic Development.

About Ciphergen

Ciphergen develops, manufactures and markets a family of ProteinChip® Systems and services for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra process chromatography division. ProteinChip Systems and Biomarker Discovery Center® collaborative services enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease. Additional information about Ciphergen can be found at www.ciphergen.com.

Safe Harbor Statement

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements, including statements regarding the scope of Novartis` use of Ciphergen`s technology and services, including the drug response study, and future growth in the field of proteomics. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the risk that biomarkers are not discovered which prove to have utility for clinical and preclinical drug development, the risk that Novartis may not choose to outsource additional projects under the master agreement, and the continued emergence of proteomics as a major focus of biological research and drug discovery. Investors should consult Ciphergen`s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2001 and Form 10-Q for the quarter ended June 30, 2002, for further information regarding these and the other risks of the Company`s business.

NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc.

Make Your Opinion Count - Click Here




--------------------------------------------------------------------------------
Source: Ciphergen Biosystems, Inc.

[panik]

When The Bio Chips Are Down
Matthew Herper, 11.06.02, 8:30 AM ET

NEW YORK - Call it the other telecom bust. In the late 1990s, three phone technology companies, Motorola, Corning and Agilent, all decided to get into the business of making DNA chips, tiny bits of glass that help laboratory scientists link genes to disease.

It looked like Santa Clara, Calif.-based Affymetrix (nyse: AFFX - news - people ), which established the market for DNA chips in the early 1990s, was about to get crushed by the trio of multibillion-dollar companies. But a funny thing happened on the way to the genome: Motorola (nyse: MOT - news - people ) and Corning (nyse: GLW - news - people ) fell out of the running altogether, and Agilent (nyse: A - news - people ) managed to capture only a small sliver of the DNA chip market.

Banc of America Securities analyst Jim Reddoch says Affymetrix still has the vast majority of the DNA chip market. While Corning was reporting a $270 million loss and cutting 2,200 jobs, Affymetrix, which is off 36% from its 52-week high, beat analyst expectations with a third-quarter profit of $619,000, or 1 cent per share. Affymetrix sells for 59 times estimated 2003 profits of 45 cents per share.

Reddoch notes that Agilent doesn`t disclose its DNA chip sales, but he estimates it has a mere 10% of the market. Affymetrix, he says, has at least 50%. Its main competition is not another company, but frugal scientists themselves. Drug company researchers may use Affymetrix chips, but many academics make their own. Reddoch sees this as an opportunity for growth, as he believes academics will be lured by the prospect of a standard chip to use for exchanging genetic data.

"Not at this price they won`t," argues David Botstein, professor in the department of genetics at Stanford Univerisity. "Your average NIH grant is $200,000. You can hardly do anything at $1,000 a chip." Botstein says.

"It doesn`t cost people $1,000 a chip anymore," says Stephen Foder, chairman and chief executive at Affymetrix. "You can get chips anywhere from $100 to $500." More than that, Fodor says, sales to academics have increased dramatically in the past two years. In the last 12 months alone, they have doubled. Prominent biologists at places like the Massachusetts Institute of Technology are using Affymetrix chips.

One company that won`t be ignoring academics is Fremont, Calif.-based Ciphergen Biosystems (nasdaq: CIPH - news - people ), which makes a next-generation "lab-on-a-chip." "Scientific progress occurs at the biology bench top," says Chief Executive William Rich, who is relying on biologists in the laboratory to flock to his chips.

DNA chips focus on the genetic code, in which genes are recipes for proteins, the chemicals that actually do the work of creating and recreating living things. Instead of looking at genes, Ciphergen`s ProteinChip provides a way of looking at which proteins are present in the cell. Better yet, it does so in a box that`s small enough that an individual biochemist can have one in front of his workstation.

Ciphergen`s approach may already be bearing fruit. The biotechnology company got a taste of success when David Ho, a world-renowned AIDS researcher, used the ProteinChip to find a protein that may give some people resistance to the HIV virus. Some of Ho`s colleagues doubt that he has the right protein, but if he does, that could give Ciphergen`s prospects a boost by providing proof that its technology really does work.

Eric Schmidt, analyst at SG Cowen, predicts Ciphergen will eke out a slight profit in 2004. "They have top-line sales growth of 70% for the last six quarters running," he says. Ciphergen is off 62% from its 52-week high.

[amazing]

wirklich TOP NEWS!!!!
für mich ist ciphergen ein klarer kauf!!!!

[panik]

Ciphergen Announces Settlement of Lawsuit
Thursday May 29, 8:59 pm ET
Settlement Provides Ciphergen Undisputed, Exclusive Rights to Baylor Patents Related to SELDI Technology


FREMONT, Calif., May 29 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) today announced settlement of its lawsuit with LumiCyte, Inc. and Molecular Analytical Systems, Inc. whereby Ciphergen acquires the exclusive rights granted to Molecular Analytical Systems under patents licensed from Baylor College of Medicine. These patent rights refer to technology known as SELDI-TOF-MS, and provide Ciphergen with an exclusive worldwide license and right to sublicense the technology and to commercialize any and all products, information and services derived from the technology without limitation. Furthermore, LumiCyte has assigned all rights granted to it from Molecular Analytical Systems and related to the Baylor College of Medicine patents to Ciphergen without restriction.
ADVERTISEMENT


William E. Rich, President and CEO of Ciphergen stated, "This settlement provides us with full exclusivity and freedom to exploit SELDI ProteinChip® technology, including the right to expand our rapidly growing Biomarker Discovery Center® services business to other potentially lucrative markets such as development of protein-based clinical diagnostics, theranostics and drug discovery products."

Under the terms of the settlement, the parties have released all claims against each other. In addition, Ciphergen will pay approximately $3 million in cash and issue approximately 1.25 million shares of Ciphergen stock to LumiCyte and will provide royalty payments, based on revenues, of up to $10 million over a 10-year period to Molecular Analytical Systems.

About Ciphergen

Ciphergen develops, manufactures and markets a family of ProteinChip® Systems and services for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra process chromatography division. ProteinChip Systems and Biomarker Discovery Center® collaborative services enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease. Additional information about Ciphergen can be found at www.ciphergen.com.

Safe Harbor Statement

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements, including statements regarding our ability to exploit our intellectual property and technology, the Company`s Biomarker Discovery Center business and future growth in the field of proteomics. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the Company`s ability to obtain additional Biomarker Discovery Collaborations, ProteinChip technology`s ability to discover protein biomarkers that have diagnostic, theranostic and/or drug discovery and development utility, the continued emergence of proteomics as a major focus of biological research and drug discovery, and our ability to protect and promote our proprietary technologies. Investors should consult Ciphergen`s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2002 and Form 10-Q for the quarter ended March 31, 2003 for further information regarding these and the other risks of the Company`s business.

NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center and BioSepra are registered trademarks of Ciphergen Biosystems, Inc.




--------------------------------------------------------------------------------
Source: Ciphergen

[panik]

Ciphergen Announces Breakthrough in Protein Interaction Discovery and Assay Capabilities
Monday June 2, 4:15 pm ET
Interaction Discovery Mapping(TM) Platform for SELDI ProteinChip(R) Systems Introduced


FREMONT, Calif., June 2 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) announced today the launch of its new Interaction Discovery Mapping (IDM) platform based on the SELDI ProteinChip Biomarker System. The IDM platform represents a significant development in Clinical Proteomics application tools, enabling rapid protein interaction studies and complementing Ciphergen`s proven Expression Difference Mapping(TM) (EDM) capability for biomarker discovery. The IDM platform enables:
-- Rapid discovery of new protein interaction related biomarkers;
-- Elucidation of disease associated biological pathways and function, as
well as novel therapeutic strategies; and
-- Development of rapid, quantitative multi-marker assays for disease
diagnosis, prognosis and treatment monitoring with improved clinical
sensitivity and specificity.


"Ciphergen has pioneered the field of Clinical Proteomics through our ProteinChip System-based biomarker discovery capabilities," commented William Rich, President and CEO. "We believe that this new IDM platform, when integrated with our proven EDM platform, combines protein expression and interaction discovery on a single ProteinChip platform and enables a breakthrough in `Functional Proteomics.` Reducing Functional Proteomics to practice in this way provides a better understanding of disease pathways and takes Clinical Proteomics to the next level."

The EDM/IDM integrated strategy for the discovery of disease-associated biomarkers is at the heart of Clinical Proteomics. This strategy is as follows:

-- Expression Difference Mapping (EDM): Ciphergen`s ProteinChip Biomarker
System is used with appropriate sample sets (disease vs. controls) to
perform EDM and discover biomarkers that are up- or down-regulated in
the disease or toxicity being studied. Using EDM and Biomarker
Patterns(TM) Software for pattern recognition, multiple protein
biomarkers of disease states are typically uncovered and study
validation is easily achieved with larger sample sets. Full automation
to improve throughput and reproducibility was recently incorporated in
this well established process by the introduction of the ProteinChip
AutoBiomarker System.
-- Purification/ID: Key disease classifying biomarkers of interest
identified with Biomarker Patterns Software are then purified and
sequence-identified using either the ProteinChip Biomarker System or a
Tandem Mass Spectrometer outfitted with a ProteinChip Interface.
SELDI-assisted sample purification is key to this process and utilizes
a range of "surface chemistry matched" BioSepra(R) Chromatography Beads
that mimic the binding and elution conditions of the ProteinChip Array
on which the biomarker was identified. This enables simple and rapid
enrichment of proteins to be isolated and digested for sequence
identification.
-- Interaction Discovery Mapping (IDM): The purified and identified
protein biomarkers are then used as "bait" on Ciphergen`s Reactive
Surface (RS) ProteinChip Arrays or Trap-eZe(TM) Affinity Beads; a new,
preactivated bead that covalently binds bait molecules or antibodies.
These beads utilize a proprietary zirconia-based support, whose density
facilitates easy handling in either spin-column or 96 well formats for
automation. Importantly, tags and labels, which can interfere with
subsequent binding events, are not necessary. After specific protein
capture from the disease sample, the captured protein and any stable
protein complexes are eluted from the bead surface and recaptured onto
ProteinChip Arrays for final quantitative SELDI analysis.
Alternatively, when the additional binding capacity of the beads is not
needed, the bait molecule can be coupled directly to Ciphergen`s next
generation preactivated RS-ProteinChip Array surface for rapid, simple
capture and direct SELDI detection of interactors from small sample
volumes. For HIS-tagged protein capture and signal transduction
applications, protocols have been developed using the company`s new
IMAC HyperCel(R) media. This new media also complements the IMAC30
ProteinChip Array for direct on-chip capture applications in similar
areas of study.


"The use of high capacity affinity beads that are `surface chemistry matched` with ProteinChip Arrays is a powerful and versatile combination. Their use for IDM applications alone or with EDM/IDM strategies enable the successful use of SELDI ProteinChip technology in applications where the most powerful tools for protein biomarker discovery, validation, purification/ID and assay development are required," stated Kate Gilbert, Consumables Product Manager.

The new IDM platform is accompanied by a detailed 100 page IDM Guide containing robust protocols for a wide range of applications such as antibody-antigen interactions, cytokine and A-beta assays, kinase assays, capture of biotinylated molecules and disease biomarker interaction discovery. These IDM protocols and the EDM/IDM strategy are routinely used by scientists at Ciphergen`s Biomarker Discovery Center® facilities in California, Pennsylvania, Denmark and Japan.

About Ciphergen

Ciphergen develops, manufactures and markets a family of ProteinChip® Systems and services for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra® process chromatography division. ProteinChip Systems and Biomarker Discovery Center® collaborative services enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease. Additional information about Ciphergen can be found at www.ciphergen.com.

Safe Harbor Statement

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements, including statements regarding the use of ProteinChip technology to identify protein biomarkers that might be developed and marketed as diagnostic tests or which might have therapeutic utility, and future growth in the field of proteomics. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ProteinChip technology`s ability to discover protein biomarkers that can be demonstrated to have diagnostic utility and which can be converted into diagnostic tests or which might have therapeutic utility, and the continued emergence of proteomics as a major focus of biological research and drug discovery. Investors should consult Ciphergen`s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2002 and Form 10-Q for the quarter ended March 31, 2003, for further information regarding these and the other risks of the Company`s business.

NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center, HyperCel and BioSepra are registered trademarks of Ciphergen Biosystems, Inc.




--------------------------------------------------------------------------------
Source: Ciphergen Biosystems, Inc.

[panik]

Ciphergen`s ProteinChip(R) Technology Employed in Fight Against SARS
Tuesday June 3, 4:15 pm ET


FREMONT, Calif., June 3 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) announced today that its ProteinChip Technology is being employed by multiple groups, including Health Canada`s National Microbiology Lab, Beijing Clinical SARS Testing Center and the Genomic Institute of Singapore, in the hunt for novel protein biomarkers associated with Severe Acute Respiratory Syndrome (SARS). Ciphergen`s Field Scientists and Biomarker Discovery Center® personnel are providing technical support for these projects, as appropriate. In general, these groups are employing Ciphergen`s patented Expression Difference Mapping(TM) protocols on nasopharyngeal (throat swabs), serum and other samples using the ProteinChip System with an initial goal of discovering protein biomarkers that could be used as rapid diagnostic tests. A number of potential biomarkers have already been discovered in SARS patient samples. These biomarkers are being identified and will be further evaluated for their utility in developing accurate diagnostic tests for SARS. If successful, therapeutic and/or vaccine strategies based on insights provided from these biomarkers may be pursued as well.
ADVERTISEMENT


In the space of only a few months, over 8300 cases of the SARS virus have been reported in 30 countries, with over 750 suspected deaths to date. A worldwide effort has been mobilized to deal with this potential epidemic; much of that effort to date has focused on sequencing the corona virus genome, which is suspected to be responsible for SARS. A number of groups have publicized gene-based approaches to diagnosing SARS; however, these approaches currently show significant false negative results.

William E. Rich, President and CEO of Ciphergen Biosystems, stated, "We have had considerable success in the past in applying our technology to various clinical questions in the infectious disease area, such as our work on HIV with the Aaron Diamond AIDS Research Center, and ProteinChip technology is now being actively employed to SARS research as well."

Working in collaboration with Health Canada, Ciphergen has also used ProteinChip technology to identify one of the SARS coronavirus proteins. This protein corresponds to an amino acid sequence encoded by the genome of the SARS coronavirus TOR2 isolate published by the Genome Sciences Centre, and it reacts with antibodies from the blood of SARS patients. Ciphergen sequenced parts of the protein and determined the mass of protein fragments on a ProteinChip tandem MS interface. Comparison of this information with genome sequence information confirmed the protein`s identity. A patent application has been filed on the protein.

About Ciphergen

Ciphergen develops, manufactures and markets a family of ProteinChip® Systems and services for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra process chromatography division. ProteinChip Systems and Biomarker Discovery Center® collaborative services enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease. Additional information about Ciphergen can be found at www.ciphergen.com.

Safe Harbor Statement

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements, including statements regarding the use of ProteinChip technology to discover useful protein biomarkers associated with SARS and develop diagnostic assays or therapeutics and/or vaccines, and future growth in the field of proteomics. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ProteinChip technology`s ability to validate these protein biomarkers as diagnostic assays and to successfully develop therapeutics and/or vaccines that have utility, the continued emergence of proteomics as a major focus of biological research and drug discovery, and our ability to protect and promote our proprietary technologies. Investors should consult Ciphergen`s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2002 and Form 10-Q for the quarter ended March 31, 2003, for further information regarding these and the other risks of the Company`s business.

NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center, HyperCel and BioSepra are registered trademarks of Ciphergen Biosystems, Inc.




--------------------------------------------------------------------------------
Source: Ciphergen Biosystems, Inc.

[panik]

Leading Canadian Clinical Research Group Licenses Ciphergen`s ProteinChip(R) Technology to Develop and Commercialize Diagnostics
Wednesday June 4, 4:15 pm ET
Ciphergen Grants Diagnostic Biomarker Discovery and Commercialization Licenses To Toronto Medical Laboratories


FREMONT, Calif., June 4 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) announced today that Toronto Medical Laboratories (TML) has acquired Ciphergen`s AutoBiomarker ProteinChip System, with an objective of pursuing targeted assay development projects aimed at identifying new protein biomarkers that can be converted into commercial diagnostic tests as part of the TML reference lab business strategy. Ciphergen has granted TML, in conjunction with the ProteinChip System, a Diagnostic Biomarker Discovery license as well as a commercial Diagnostic Assay Platform license to perform paid clinical diagnostic tests using this platform. Financial and other terms were not disclosed.
ADVERTISEMENT
ATTENTION ACTIVE TRADERS

· 30 commission-free trades
New account special offer
· Enjoy FREE real-time data
Get Ameritrade Streamer®.
· Join Ameritrade Apex
Now trade first class

See all that Ameritrade offers
Open your account now





TML was established in 1995 as a joint venture between the University Health Network (comprised of Toronto General Hospital, Toronto Western and Princess Margaret Hospital) and MDS Inc. Through the collaboration of the UNH and MDS, TML has established a solid foundation of hospital contracts and positioned itself as a leading public / private laboratory partnership in Canada. Today, its team performs more than 9 million diagnostic tests on medical specimens per year. TML medical and scientific staff have been instrumental in many diagnostic breakthroughs and have a strong track record in translating bench research into clinically beneficial diagnostic tests.

The McLaughlin Centre for Molecular Medicine at the University of Toronto is an equal partner with TML in this investment and will share in the use of the ProteinChip technology. This Centre is a partnership of five Toronto teaching centers including The University of Toronto, University Health Network, Hospital for Sick Children, Mount Sinai Hospital and Sunnybrook and Women`s Health Science Center. The Centre is focused on advancing health through the application of molecular advances to clinical care.

Projects under discussion using the ProteinChip System by TML and the McLaughlin Centre include studies on large organ transplant rejection markers, the early diagnosis of endometrial, thyroid and lung cancer, and the identification of predictors of response to novel therapeutic agents in colon cancer, leukemia and myeloma.

William Rich, President and CEO of Ciphergen, stated, "We are delighted that such prestigious groups within Canada have decided to utilize our technology with a goal of developing new diagnostic tests. TML, UHN, MDS and the researchers associated with the McLaughlin Centre have impressive track records of success and are not only interested in pursuing leading edge research, but are committed to translate this research to medical practice."

Ene Underwood, President of Toronto Medical Laboratories, commented, "We`re very excited to be incorporating the ProteinChip technology as a new platform in our laboratories. We believe this technology offers tremendous potential in the worldwide efforts to unleash the diagnostic potential of proteomics."

About Ciphergen

Ciphergen develops, manufactures and markets a family of ProteinChip® Systems and services for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra process chromatography division. ProteinChip Systems and Biomarker Discovery Center® collaborative services enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease. Additional information about Ciphergen can be found at www.ciphergen.com.

Safe Harbor Statement

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements, including statements regarding the use of ProteinChip technology to identify protein bioimarkers that might be developed and marketed as diagnostic tests and future growth in the field of proteomics. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ProteinChip technology`s ability to discover protein biomarkers that can be demonstrated to have diagnostic utility and which can be converted into diagnostic tests, and the continued emergence of proteomics as a major focus of biological research and drug discovery. Investors should consult Ciphergen`s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2002 and Form 10-Q for the quarter ended March 31, 2003, for further information regarding these and the other risks of the Company`s business.

NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center, HyperCel and BioSepra are registered trademarks of Ciphergen Biosystems, Inc.




--------------------------------------------------------------------------------
Source: Ciphergen Biosystems, Inc.

[panik]

Ciphergen Launches the First `Matrix-Free` ProteinChip(R) Array At the 2003 ASMS Meeting
Monday June 9, 4:15 pm ET
Revolutionary Advance in SELDI - TOF - Mass Spectrometry IDM


MONTREAL, June 9 /PRNewswire-FirstCall/ -- Amongst 26 presentations and posters referencing Ciphergen`s SELDI ProteinChip® technology at the 51st Annual Conference on Mass Spectrometry and Allied Topics held by the American Society for Mass Spectrometry, Ciphergen Biosystems (Nasdaq: CIPH - News) announced the commercial launch of a new line of SEND ProteinChip Arrays which vastly improve the applicability of SELDI-TOF-MS. The new biochip product family, incorporating Surface Enhanced Neat Desorption (SEND) technology, represents a revolutionary advance for Laser Desorption/Ionization Mass Spectrometry, enabling SELDI-TOF-MS based metabolomics and greatly enhancing MS based protein ID. In SEND, the Energy Absorbing Molecule (EAM) or "matrix" is incorporated in the surface chemistry of the array. The result is that the chemical noise introduced by the application of EAM is significantly reduced, enabling low molecular weight species to be detected with greatly improved signal-to-noise while also minimizing the variability associated with matrix addition.
ADVERTISEMENT


The first SEND product launched, named "SEND ID," is targeted to peptide mass fingerprinting applications for identification of digested proteins. The array has also been used for the analysis of small, polar molecules. SEND ID contains a hydrophobic interaction functional group to enable "on-chip" clean-up of samples. Most other approaches to this application require clean-up of the sample in a small chromatography column in addition to pre-mixing with matrix. By avoiding these steps with SEND ID, work flow is simplified and losses of sticky peptides are minimized. In addition, the suppression of interfering matrix signal results in superior sensitivity and improved sequence coverage. In comparative studies between SEND technology and traditional MALDI, protein digests are routinely detected at around 10x better sensitivity and with up to 90% sequence coverage.

The SEND ID ProteinChip Array represents a significant addition to the utility of SELDI for protein identification using either Ciphergen`s full-capability ProteinChip Systems or Ciphergen`s SELDI ProteinChip Interface for Tandem MS instrumentation. Studies of SEND ID arrays used in conjunction with the ProteinChip Interface for the ABI-Sciex QSTAR® instrument show excellent capability to produce peptide mass fingerprints and then directly sequence individual peptides of interest. These protein identification tools provide an important complement to the proven biomarker discovery capability of Ciphergen`s ProteinChip Systems.

"SEND ID represents the first step towards a completely matrix-free world for Laser Desorption/Ionization Mass Spectrometry. The reduction in chemical noise and the removal of a step in the protocol that can add variability to the process has the potential to vastly improve the use of LDI MS for most protein and peptide studies. Ciphergen is now developing a variety of functionalized SEND surfaces and new SELDI applications. Future products envisioned will include reversed phase, HIC, ion exchange, IMAC and protein interaction capabilities for protein, peptide and small organic molecule applications," says William E. Rich, President and CEO of Ciphergen Biosystems.

Relevant to the SEND technology, Ciphergen was awarded United States Patent 5,894,063 directed to methods of desorbing large and small biomolecules without the need to apply external energy absorbing molecules (matrix) in June of 1999.

About Ciphergen

Ciphergen develops, manufactures and markets a family of ProteinChip® Systems and services for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra process chromatography division. ProteinChip Systems and Biomarker Discovery Center® collaborative services enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease. Additional information about Ciphergen can be found at www.ciphergen.com.

Safe Harbor Statement

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements, including statements regarding the use of SEND Arrays to perform metabolomics and identify proteins, future SEND product introductions and future growth in the field of proteomics. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including SEND technology`s ability to successfully perform metabolomics and improve protein identification results, Ciphergen`s ability to develop and introduce future SEND surfaces and applications that have utility and meet with customer acceptance, the continued emergence of proteomics as a major focus of biological research and drug discovery, and our ability to protect and promote our proprietary technologies. Investors should consult Ciphergen`s filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2002 and Form 10-Q for the quarter ended March 31, 2003, for further information regarding these and the other risks of the Company`s business.

NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center and BioSepra are registered trademarks of Ciphergen Biosystems, Inc.




--------------------------------------------------------------------------------
Source: Ciphergen Biosystems, Inc.

[Xepher]

Hallo ist da jemand??? Bin schon seid Wochen in Ciph investiert. Scheint in Deutschland wirklich noch unentdeckt zu sein....